Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial.
Donald Williams ParsonsKatherine A JanewayDavid R PattonCynthia L WinterBrent CoffeyP Mickey WilliamsSinchita Roy-ChowdhuriGregory J TsongalisMark J RoutbortNilsa C RamirezLauren SaguiligJin PiaoTodd A AlonzoStacey L BergElizabeth FoxDouglas S HawkinsJeffrey S AbramsMargaret MooneyNaoko TakebeJames V TricoliNita L Seibelnull nullPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
The Pediatric MATCH trial has proven the feasibility of a nationwide screening Protocol for identification of actionable genetic alterations and assignment of pediatric and young adult patients with refractory cancers to trials of molecularly targeted therapies. These data support the early use of tumor molecular screening for childhood patients with cancer whose tumors have not responded to standard treatments.